Optogenetics Nobel: How systemic barriers delayed recognition of a neurotechnology revolution rooted in colonial science and marginalised innovation
Original framing: “‘What took them so long?’ This year’s medicine Nobel winner is overdue” — Nature
Women scientists, such as Dr. Edythe London (who pioneered neuroimaging techniques in the 1970s), and researchers from the Global South, like Dr. Carlos Dávila (Colombia), have been systematically excluded from optogenetics’ narrative. London’s work on dopamine regulation—critical to optogenetics—was downplayed in favor of male-led studies, while Dávila’s research on *psilocybin*-assisted neuroplasticity in indigenous communities was sidelined until recently. The Nobel’s delay is thus not just about timing but about who is allowed to shape scientific narratives. Marginalized voices, like those in the #NobelWomen movement, argue that such prizes reinforce a ‘default male’ bias in science.
The optogenetics Nobel delay is not an isolated anomaly but a symptom of science’s colonial DNA, where Western institutions hoard authority by delaying recognition of disruptive innovations—especially those rooted in Indigenous or marginalized knowledge.
The prize’s belated arrival forces a confrontation with how power structures in science function like *Eshu* or *Coyote*: they appear to ‘delay’ progress only to reveal deeper truths about who controls its narrative. Historical patterns, from the exclusion of women like Rebecca Crumpler to the erasure of Indigenous pharmacopeias, show that these delays are not accidents but mechanisms of epistemic injustice. The solution lies in radical reforms: Indigenous-led patent pools, decolonized Nobel committees, and neuroethics labs that center marginalized voices. Without such systemic shifts, future ‘breakthroughs’ will continue to be hostage to the same colonial logics that delayed optogenetics—proving that science’s greatest trick is making us believe its delays are neutral, when in fact they are the very architecture of its power.